1. Home
  2. LEGN vs GKOS Comparison

LEGN vs GKOS Comparison

Compare LEGN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • GKOS
  • Stock Information
  • Founded
  • LEGN 2014
  • GKOS 1998
  • Country
  • LEGN United States
  • GKOS United States
  • Employees
  • LEGN N/A
  • GKOS N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • GKOS Medical/Dental Instruments
  • Sector
  • LEGN Health Care
  • GKOS Health Care
  • Exchange
  • LEGN Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • LEGN 5.4B
  • GKOS 5.8B
  • IPO Year
  • LEGN 2020
  • GKOS 2015
  • Fundamental
  • Price
  • LEGN $38.80
  • GKOS $86.16
  • Analyst Decision
  • LEGN Strong Buy
  • GKOS Strong Buy
  • Analyst Count
  • LEGN 11
  • GKOS 12
  • Target Price
  • LEGN $74.60
  • GKOS $131.17
  • AVG Volume (30 Days)
  • LEGN 1.4M
  • GKOS 1.2M
  • Earning Date
  • LEGN 08-11-2025
  • GKOS 07-30-2025
  • Dividend Yield
  • LEGN N/A
  • GKOS N/A
  • EPS Growth
  • LEGN N/A
  • GKOS N/A
  • EPS
  • LEGN N/A
  • GKOS N/A
  • Revenue
  • LEGN $728,303,000.00
  • GKOS $432,953,000.00
  • Revenue This Year
  • LEGN $65.33
  • GKOS $27.88
  • Revenue Next Year
  • LEGN $54.68
  • GKOS $27.76
  • P/E Ratio
  • LEGN N/A
  • GKOS N/A
  • Revenue Growth
  • LEGN 112.46
  • GKOS 26.70
  • 52 Week Low
  • LEGN $27.34
  • GKOS $77.10
  • 52 Week High
  • LEGN $59.62
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 47.38
  • GKOS 25.67
  • Support Level
  • LEGN $38.53
  • GKOS $93.57
  • Resistance Level
  • LEGN $45.30
  • GKOS $97.76
  • Average True Range (ATR)
  • LEGN 1.76
  • GKOS 3.37
  • MACD
  • LEGN -0.61
  • GKOS -1.42
  • Stochastic Oscillator
  • LEGN 9.73
  • GKOS 14.76

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: